Cargando…

The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy

BACKGROUND: The clinical values of inflammatory and nutritional markers remained unclear for gastric cancer with neoadjuvant chemotherapy (NACT). METHODS: The inflammatory, nutritional markers and their changes were analyzed for locally advanced gastric cancer with NACT. The predictive value was eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ziyu, Li, Shuangxi, Ying, Xiangji, Zhang, Lianhai, Shan, Fei, Jia, Yongning, Ji, Jiafu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165147/
https://www.ncbi.nlm.nih.gov/pubmed/32072387
http://dx.doi.org/10.1007/s10120-019-01027-6
_version_ 1783523418951385088
author Li, Ziyu
Li, Shuangxi
Ying, Xiangji
Zhang, Lianhai
Shan, Fei
Jia, Yongning
Ji, Jiafu
author_facet Li, Ziyu
Li, Shuangxi
Ying, Xiangji
Zhang, Lianhai
Shan, Fei
Jia, Yongning
Ji, Jiafu
author_sort Li, Ziyu
collection PubMed
description BACKGROUND: The clinical values of inflammatory and nutritional markers remained unclear for gastric cancer with neoadjuvant chemotherapy (NACT). METHODS: The inflammatory, nutritional markers and their changes were analyzed for locally advanced gastric cancer with NACT. The predictive value was evaluated by the Cox proportional hazards regressions under three hypothesized scenarios. The nomograms including independent prognostic factors were plotted for survival prediction. RESULTS: A total of 225 patients were included in the study. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index, and hemoglobin (Hgb) were significantly reduced, and the body mass index was significantly increased after NACT (all P < 0.05). The pre-NACT NLR [hazard ratio (HR) = 1.176, P = 0.059] showed a trend to correlate with the overall survival (OS) when only pre-NACT markers available; The post-NACT Hgb (HR = 0.982, P = 0.015) was the independent prognostic factor when only post-NACT markers available; The post-NACT Hgb (HR = 0.984, P = 0.025) and the change value of LMR (HR = 1.183, P = 0.036) were the independent prognostic factors when both pre- and post-NACT markers available. The nomogram had a similar Harrell’s C-statistic compared to ypTNM stage (0.719 vs. 0.706). CONCLUSION: For locally advanced gastric cancer, the NACT could significantly decrease some inflammatory markers. The pre-NACT NLR, the post-NACT Hgb and the change value of LMR had some values in survival prediction combined with age, sex, tumor location and the clinical stages under different clinical scenarios. The elevated initial NLR, the preoperative anemia and the greater change value of LMR implied a poor prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10120-019-01027-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7165147
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-71651472020-04-24 The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy Li, Ziyu Li, Shuangxi Ying, Xiangji Zhang, Lianhai Shan, Fei Jia, Yongning Ji, Jiafu Gastric Cancer Original Article BACKGROUND: The clinical values of inflammatory and nutritional markers remained unclear for gastric cancer with neoadjuvant chemotherapy (NACT). METHODS: The inflammatory, nutritional markers and their changes were analyzed for locally advanced gastric cancer with NACT. The predictive value was evaluated by the Cox proportional hazards regressions under three hypothesized scenarios. The nomograms including independent prognostic factors were plotted for survival prediction. RESULTS: A total of 225 patients were included in the study. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index, and hemoglobin (Hgb) were significantly reduced, and the body mass index was significantly increased after NACT (all P < 0.05). The pre-NACT NLR [hazard ratio (HR) = 1.176, P = 0.059] showed a trend to correlate with the overall survival (OS) when only pre-NACT markers available; The post-NACT Hgb (HR = 0.982, P = 0.015) was the independent prognostic factor when only post-NACT markers available; The post-NACT Hgb (HR = 0.984, P = 0.025) and the change value of LMR (HR = 1.183, P = 0.036) were the independent prognostic factors when both pre- and post-NACT markers available. The nomogram had a similar Harrell’s C-statistic compared to ypTNM stage (0.719 vs. 0.706). CONCLUSION: For locally advanced gastric cancer, the NACT could significantly decrease some inflammatory markers. The pre-NACT NLR, the post-NACT Hgb and the change value of LMR had some values in survival prediction combined with age, sex, tumor location and the clinical stages under different clinical scenarios. The elevated initial NLR, the preoperative anemia and the greater change value of LMR implied a poor prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10120-019-01027-6) contains supplementary material, which is available to authorized users. Springer Singapore 2020-02-18 2020 /pmc/articles/PMC7165147/ /pubmed/32072387 http://dx.doi.org/10.1007/s10120-019-01027-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Li, Ziyu
Li, Shuangxi
Ying, Xiangji
Zhang, Lianhai
Shan, Fei
Jia, Yongning
Ji, Jiafu
The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy
title The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy
title_full The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy
title_fullStr The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy
title_full_unstemmed The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy
title_short The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy
title_sort clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and d2 lymphadenectomy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165147/
https://www.ncbi.nlm.nih.gov/pubmed/32072387
http://dx.doi.org/10.1007/s10120-019-01027-6
work_keys_str_mv AT liziyu theclinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT lishuangxi theclinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT yingxiangji theclinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT zhanglianhai theclinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT shanfei theclinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT jiayongning theclinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT jijiafu theclinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT liziyu clinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT lishuangxi clinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT yingxiangji clinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT zhanglianhai clinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT shanfei clinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT jiayongning clinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy
AT jijiafu clinicalvalueandusageofinflammatoryandnutritionalmarkersinsurvivalpredictionforgastriccancerpatientswithneoadjuvantchemotherapyandd2lymphadenectomy